Armata Pharmaceuticals' AP-SA02 Gets FDA Breakthrough Therapy Designation

07:46 AM EDT, 09/14/2026 (MT Newswires) -- Armata Pharmaceuticals (ARMP) said Monday that AP-SA02 was granted Breakthrough Therapy designation by the US Food and Drug Administration for adjunct treatment of complicated Staphylococcus aureus bacteremia, or SAB, caused by methicillin-sensitive S. aureus or methicillin-resistant S. aureus. The designation enables an expedited review of medicines that treat a serious or life-threatening condition and have shown preliminary clinical evidence of potential substantial improvement over available therapies, the company said. Armata said the designation was supported by Phase 1b/2a clinical data, which showed that patients treated with AP-SA02 and the best available antibiotic therapy demonstrated higher and earlier clinical cure rates than those who received a placebo and the best available antibiotic therapy. The company added that patients treated with AP-SA02 also demonstrated favorable trends across several measures of disease resolution. Shares of the company were up 12% in Monday's premarket activity.